



REFERENCES

1. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. *Allergy*. 2018;73:1575-1596.
2. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. *Biochem Biophys Res Commun*. 2006;343:1286-1289.
3. Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. *Clin Immunol*. 2011;141:31-35.
4. Kiss N, Barabás E, Várnai K, et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. *Clin Immunol*. 2013;149:142-145.
5. Veronez CL, Moreno AS, Constantino-Silva RN, et al. Hereditary angioedema with normal C1 inhibitor and F12 mutations in 42 Brazilian families. *J Allergy Clin Immunol Pract*. 2017 Nov 8. pii: S2213-2198(17)30755-9. <https://doi.org/10.1016/j.jaip.2017.09.025>. [Epub ahead of print]
6. Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. *Allergy*. 2015;70:1004-1012.
7. Bork K, Wulff K, Steinmüller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. *Allergy*. 2018;73:442-450.
8. Dewald G. A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor. *Biochem Biophys Res Commun*. 2018;498:193-198.
9. Bafunno V, Firinu D, D'Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. *J Allergy Clin Immunol*. 2018;141:1009-1017.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

DOI: 10.1111/all.13551

Maternal pregestational or gestational diabetes and childhood wheezing: A population-based cohort study

To the Editor,

Early-life exposures that modify intrauterine environment may influence the development of wheezing and asthma in children. Diabetes may be one of these compromising factors, possibly through mechanisms related to alterations in fetal allergen sensitization and lung maturation disruption.^{1,2} Previous studies on diabetes and offspring wheezing/asthma have revealed contradicting findings.^{3,4} Until now, no studies have examined whether the association between maternal diabetes and childhood wheezing/asthma varies by both types of diabetes and wheezing/asthma phenotypes.

1 | METHODS

We conducted a register-based cohort study, utilizing data from all Danish residents. We identified 569 649 liveborn singletons during 1996-2004 from the Danish Medical Birth Registry. We excluded 3954 children with missing or gestational age <22 weeks or >45 weeks, 18 244 children who emigrated, and 2774 children who died before their 6th birthday.

We retrieved information on diabetes diagnoses from the Danish National Diabetes Register, which contains information on patients with diabetes treated in either primary or hospital care in Denmark. We additionally identified mothers with gestational diabetes (ICD-10 code O24.4) in the Danish National Patient Register (DNPR). Type of diabetes was categorized as pregestational or gestational diabetes according to the timing of first treatment. We further classified pregestational diabetes into type 1 or type 2 diabetes (Figure S1):

1. According to the DNPR diagnosis if the mother had one type of diabetes diagnosis recorded.
2. For those first diagnosed after 1995 and with no record in the DNPR, or those with both type 1 and type 2 diabetes records: according to first-time antidiabetic prescription, insulin for type 1 diabetes, and oral antidiabetics for type 2 diabetes.
3. For those remaining, with undetermined diabetes type, we used age at first-time diabetes treatment <30 and ≥30 years as the cutoff for type 1 and type 2 diabetes, respectively.⁵

Our outcomes of interest were childhood wheezing phenotypes determined by wheezing treatment (i.e. hospital treatment for wheezing or anti-asthmatic drug treatment) during 0-3 years of age and 4-6 years similar to a previous study from our group.⁶ Information on hospital treatment was based on ICD-10 codes J45 and J46 from the DNPR and anti-asthmatic drug treatment based on Anatomical Therapeutic Chemical classification codes (Table S1) from the Danish National Prescription Registry. We defined wheezing treatment at age 0-3 years as at least two anti-asthmatic drug prescriptions within 1 year period or at least one hospital treatment for wheezing during 0-3 years. Wheezing treatment at age 4-6 years was similarly defined. We categorized children into four mutually exclusive groups:

1. *No wheezing*: no wheezing treatment;
2. *Early-onset transient wheezing*: wheezing treatment during 0-3 years of age only;
3. *Early-onset persistent wheezing*: wheezing treatment both during 0-3 years and 4-6 years of age;

TABLE 1 Characteristics of study population

Characteristics	Mothers without diabetes (n = 532 777)	Mothers with diabetes		
		Pregestational Type 1 diabetes (n = 3146)	Pregestational Type 2 diabetes (n = 841)	Gestational diabetes (n = 7913)
Maternal age at delivery (years)				
<25	80 456 (15.1)	343 (10.9)	23 (2.7)	795 (10.1)
25-29	194 368 (36.5)	1205 (38.3)	66 (7.8)	2306 (29.1)
30-34	180 595 (33.9)	1210 (38.5)	291 (34.6)	2779 (35.1)
≥35	77 358 (14.5)	388 (12.3)	461 (54.8)	2033 (25.7)
Parity				
1	229 948 (43.2)	872 (27.7)	112 (13.3)	3000 (37.9)
≥2	302 829 (56.8)	2274 (72.3)	729 (86.7)	4913 (62.1)
Maternal smoking during pregnancy				
Yes	115 440 (21.7)	703 (22.3)	161 (19.1)	1643 (20.8)
No	397 663 (74.6)	2201 (70.0)	628 (74.7)	5835 (73.7)
Missing	19 674 (3.7)	242 (7.7)	52 (6.2)	435 (5.5)
Maternal employment status at conception				
Unskilled workers or not in labor market	191 501 (35.9)	1275 (40.5)	410 (48.8)	3280 (41.5)
Skilled workers and white- collar workers	207 950 (39.0)	1272 (40.4)	257 (30.6)	3065 (38.7)
Top-level status	133 075 (25.0)	597 (19.0)	174 (20.7)	1565 (19.8)
Missing	251 (<0.1)	<5	0	<5
Calendar year of birth				
1996-1998	181 684 (34.1)	864 (27.5)	176 (20.9)	2476 (31.3)
1999-2001	178 377 (33.5)	1102 (35.0)	304 (36.2)	2461 (31.1)
2002-2004	172 716 (32.4)	1180 (37.5)	361 (42.9)	2976 (37.6)
Maternal diabetes complications before childbirth	-	1003 (31.9)	85 (10.1)	36 (0.5)
Maternal asthma before childbirth	59 809 (11.2)	482 (15.3)	135 (16.1)	1178 (14.9)
Maternal thyroid disorders before childbirth	7133 (1.3)	145 (4.6)	40 (4.8)	172 (2.2)
Preterm birth	24 614 (4.6)	739 (23.5)	106 (12.6)	608 (7.7)
Fetal growth ^a				
Small for gestational age	52 202 (9.8)	136 (4.3)	46 (5.5)	557 (7.0)
Appropriate for gestational age	428 903 (80.5)	1886 (60.0)	567 (67.4)	5664 (71.6)
Large for gestational age	51 672 (9.7)	1124 (35.7)	228 (27.1)	1692 (21.4)

Figures are numbers (%).

^aSmall for gestational age is defined as a birthweight below the 10th percentile of birthweight by the gestational age and sex, and large for gestational age as above the 90th percentile. The *P*-values for the comparison of differences among the four diabetes exposure categories were all less than 0.001, using chi-square tests.

4. Late-onset wheezing: wheezing treatment during 4-6 years of age only.

Note that for this study we termed our outcome of interest as wheezing and not asthma, acknowledging the challenges in diagnosing symptoms related to narrowing of airways and breathing problems in young children.

Statistical analyses were performed with Stata 15.0. As odds ratios tend to overestimate associations when outcomes are

common, we used log-binomial regression to analyze the data with robust standard errors, as some individuals are siblings. The magnitude of the associations of each type of maternal diabetes with each wheezing phenotype was presented as prevalence ratios (PRs). The following confounders were included: maternal age, parity, smoking during pregnancy, asthma, thyroid disorders before childbirth, employment status at conception, and child calendar year at birth. Values for covariates were missing for 3.8% of children, and we applied 20 imputations to impute missing values.




FIGURE 1 Prevalence ratios of early-onset transient, early-onset persistent, and late-onset wheezing according to type of maternal diabetes diagnosis (N = 544 677). Abbreviations: PR, prevalence ratio; CI, confidence interval. *Adjusted for maternal age at childbirth (<25, 25-29, 30-34, and ≥35 years), maternal asthma (yes/no), maternal smoking during pregnancy (yes/no), maternal parity at the index pregnancy (1st, or 2nd and above), maternal thyroid disorders before childbirth (ICD-8 codes 240-246 and ICD-10 codes E00-E07; yes/no), maternal employment status at conception (unskilled workers or not in labor market, skilled workers and white-collar workers, and top-level status), and calendar year at birth (1996-1998, 1999-2001, and 2002-2004)

2 | RESULTS

Of 544 677 children, 3146 (0.6%) were born to mothers with pregestational type 1 diabetes, 841 (0.2%) with pregestational type 2 diabetes, and 7913 (1.5%) with gestational diabetes. Table 1 shows the characteristics of the study subjects.

Gestational diabetes was associated with small increased risk of early-onset transient wheezing (adjusted PR = 1.08, 95% CI: 1.00-1.17) and early-onset persistent wheezing (PR = 1.15, 95% CI: 1.05-1.26) in offspring, compared to mothers without diabetes. Pregestational type 1 diabetes was associated with a clearly increased risk of early-onset wheezing in offspring: PRs were 1.30 (95% CI: 1.17-1.45) for early-onset transient wheezing and 1.25 (95% CI: 1.08-1.44) for early-onset persistent wheezing. Neither gestational nor type 1 diabetes was associated with offspring late-onset wheezing. We found no evidence that pregestational type 2

diabetes was associated with any wheezing phenotypes in children (Figure 1).

Altogether, 9.4% of the 11 900 children were born to mothers with diabetes complications (ketoacidosis or diabetic coma, nephropathy, retinopathy, neuropathy, or vasculopathy/angiopathy) before childbirth; these children had higher risk of early-onset transient (PR = 1.22, 95% CI: 0.97-1.52) and persistent wheezing (PR = 1.21, 95% CI: 0.91-1.61) than children of mothers without diabetes (Table S2).

The results were similar when we repeated our analyses among those with one recorded type of diabetes (Table S3). The associations of offspring wheezing phenotypes with type 1 diabetes remained unchanged after further adjustment for maternal prepregnancy body mass index, while the associations with gestational diabetes were no longer statistically significant (Figure S2).

3 | DISCUSSION

Pregestational type 1 and gestational diabetes were associated with small increased risk of early-onset transient wheezing and persistent wheezing, but not late-onset wheezing in offspring. Pregestational type 2 diabetes was not associated with any childhood wheezing phenotypes.

Currently, the underlying mechanisms behind the association between maternal diabetes and childhood wheezing are unknown. In the presence of diabetes, the fetus is exposed to abnormally high glucose levels, whereas the fetal pancreas exhibits limited responses to acute changes in cord blood glucose.⁷ This may result in fetal hyperinsulinemia and consequently hypoxia,² leading to lung maturation disruption.⁸ If this is true, we also would expect to see an impact of pregestational type 2 diabetes, which was not observed. It is possible that mothers with type 2 diabetes have better glycemic control than mothers with type 1 or gestational diabetes.⁹ Our finding of particularly increased risk in mothers with diabetes complications may implicate poor glycemic control. Additionally, type 1 diabetes is an autoimmune disease, and autoantibodies that cross the placenta may act directly on fetal lung development.¹⁰ Further research and replications are needed to validate our findings and determine the likely complex mechanisms underlying diabetes and risk of offspring wheezing.

CONFLICTS OF INTEREST

None.

FUNDING

This study is funded by an Independent Postdoc Grant to Liu X. from the Danish Council for Independent Research (Project No. DFF-5053-00156B). Agerbo E. and Munk-Olsen T. are supported by iPSYCH, the Lundbeck Foundation Initiative for Integrative Psychiatric Research (R155-2014-1724). Agerbo E. is also supported by Niels Bohr Professorship Grant from the Danish National Research Foundation and the Stanley Medical Research Institute. Li J. is supported by National Natural Science Foundation of China (81530086), the Nordic Cancer Union (176673, 186200), the Danish Council for Independent Research (DFF-6110-00019B), Karen Elise Jensens Fond (2016), and the PROCIN project (financed by the Novo Nordisk Foundation and the Lundbeck Foundation). The funders had no roles in study design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

ORCID

Xiaoqin Liu  <http://orcid.org/0000-0003-4519-1536>

Xiaoqin Liu¹ 

Esben Agerbo^{1,2,3}

Jiong Li^{4,5}

Shyamali C. Dharmage⁶

Reimar W. Thomsen⁴

Jørn Olsen^{4,7}

Trine Munk-Olsen¹

¹The National Center for Register-Based Research, Aarhus University, Aarhus, Denmark

²CIRRAU-Centre for Integrated Register-Based Research, Aarhus University, Aarhus, Denmark

³Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark

⁴Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

⁵Ministry of Education - Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

⁶Allergy and Lung Health Unit, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia

⁷Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California

Correspondence: Xiaoqin Liu, The National Center for Register-based Research, Aarhus University, Fuglesangs Allé 26, 8210 Aarhus V. Denmark (lxq@econ.au.dk).

REFERENCES

1. Kumar R, Ouyang F, Story RE, et al. Gestational diabetes, atopic dermatitis, and allergen sensitization in early childhood. *J Allergy Clin Immunol*. 2009;124:1031-1038.
2. Taricco E, Radaelli T, Rossi G, et al. Effects of gestational diabetes on fetal oxygen and glucose levels in vivo. *BJOG*. 2009;116:1729-1735.
3. Azad MB, Becker AB, Kozyrskyj AL. Association of maternal diabetes and child asthma. *Pediatr Pulmonol*. 2013;48:545-552.
4. Zugna D, Galassi C, Annesi-Maesano I, et al. Maternal complications in pregnancy and wheezing in early childhood: a pooled analysis of 14 birth cohorts. *Int J Epidemiol*. 2015;44:199-208.
5. Feltbower RG, McKinney PA, Campbell FM, Stephenson CR, Bodansky HJ. Type 2 and other forms of diabetes in 0-30 year olds: a hospital based study in Leeds, UK. *Arch Dis Child*. 2003;88:676-679.
6. Liu X, Agerbo E, Schlunssen V, Wright RJ, Li J, Munk-Olsen T. Maternal asthma severity and control during pregnancy and risk of offspring asthma. *J Allergy Clin Immunol*. 2018;141:886-892.
7. Fowden AL, Hill DJ. Intra-uterine programming of the endocrine pancreas. *Br Med Bull*. 2001;60:123-142.
8. Haworth SG, Hislop AA. Lung development-the effects of chronic hypoxia. *Semin Neonatol*. 2003;8:1-8.
9. Persaud ODD. Maternal diabetes and the consequences for her offspring. *J Develop Disabilities*. 2007;13:101-134.
10. Rottem M, Gershwin ME, Shoenfeld Y. Allergic disease and autoimmune effectors pathways. *Dev Immunol*. 2002;9:161-167.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Flowchart illustrating the classification of pregestational type 1 and type 2 diabetes




Table S1. Anatomical Therapeutical Chemical (ATC) classification codes for anti-asthmatic drugs

Anti-asthmatic drugs	ATC codes
Inhaled β 2-agonists	R03AC02, -03, -04, -12 and -13
Inhaled glucocorticoids	R03BA01, -02 and -05
Fixed-dose combinations of inhaled β 2-agonists and glucocorticoids	R03AK06 and -07
Leukotriene receptor antagonists	R03DC03
Anti-IgE treatment	R03DX05

Table S2. Prevalence ratios of offspring early-onset transient, early-onset persistent, and late-onset wheezing in children according to maternal diabetes complications before childbirth

Diabetes complications in mothers	N	Early-onset transient wheezing			Early-onset persistent wheezing			Late-onset wheezing		
		Cases	Crude PR	Adjusted PR (95% CI) [†]	Cases	Crude PR	Adjusted PR (95% CI) [†]	Cases	Crude PR	Adjusted PR (95% CI) [†]
Mothers with no diabetes	532,777	39,410 (7.4)	1	1 (ref)	26,277 (4.9)	1	1 (ref)	14,151 (2.7)	1	1 (ref)
Maternal diabetes during pregnancy										
No diabetes complications before childbirth	10,776	892 (8.3)	1.11	1.08 (1.00–1.17)	651 (6.0)	1.24	1.15 (1.05–1.26)	301 (2.8)	1.04	1.04 (0.91–1.19)
Diabetes complications *	1,124	123 (10.9)	1.48	1.22 (0.97–1.52)	73 (6.5)	1.32	1.21 (0.91–1.61)	26 (2.3)	0.85	0.96 (0.58–1.60)

Abbreviations: PR, prevalence ratio; CI, confidence interval.

*Diabetes complications include diabetic coma, ketoacidosis, nephropathy, retinopathy, neuropathy, vasculopathy/angiopathy, and other diabetes complications.

[†] Adjusted for maternal age at childbirth (<25, 25–29, 30–34, and ≥35 years), maternal asthma (yes/no), maternal smoking during pregnancy (yes/no), maternal parity at the index pregnancy (1st, or 2nd and above), maternal thyroid disorders before childbirth (ICD-8 codes 240–246 and ICD-10 codes E00–E07; yes/no), maternal employment status at conception (unskilled workers or not in labor market, skilled workers and white-collar workers, and top-level status), maternal type of diabetes (pregestational type 1 diabetes, pregestational type 2 diabetes, and gestational diabetes), and calendar year at birth (1996–1998, 1999–2001, and 2002–2004).


Table S3. Prevalence ratios of early-onset transient, early-onset persistent, and late-onset wheezing according to type of maternal diabetes among mothers with one type of diabetes diagnosis recorded in the patient register (N=542,264)

Type of diabetes in mothers	N	Early-onset transient wheezing			Early-onset persistent wheezing			Late-onset wheezing		
		Cases	Crude PR	Adjusted PR (95% CI) *	Cases	Crude PR	Adjusted PR (95% CI) *	Cases	Crude PR	Adjusted PR (95% CI) *
Mothers with no diabetes	532,777	39,410 (7.4)	1	1 (ref)	26,277 (4.9)	1	1 (ref)	14,151 (2.7)	1	1 (ref)
Any diabetes before childbirth										
Pregestational type 1 diabetes	1,354	135 (10.0)	1.35	1.35 (1.15–1.59)	86 (6.4)	1.29	1.25 (1.01–1.54)	35 (2.6)	0.97	0.96 (0.69–1.34)
Pregestational type 2 diabetes	220	15 (6.8)	0.92	0.95 (0.59–1.52)	7 (3.2)	0.65	0.66 (0.32–1.37)	7 (3.2)	1.20	1.24 (0.60–2.57)
Gestational diabetes	7,913	622 (7.9)	1.06	1.08 (1.00–1.06)	467 (5.9)	1.20	1.16 (1.06–1.26)	228 (2.9)	1.08	1.07 (0.94–1.22)

Abbreviations: PR, prevalence ratio; CI, confidence interval.

*Adjusted for maternal age at childbirth (<25, 25–29, 30–34, and ≥35 years), maternal asthma (yes/no), maternal smoking during pregnancy (yes/no), maternal parity at the index pregnancy (1st, or 2nd and above), maternal thyroid disorders before childbirth (ICD-8 codes 240–246 and ICD-10 codes E00–E07; yes/no), maternal employment status at conception (unskilled workers or not in labor market, skilled workers and white-collar workers, and top-level status), and calendar year at birth (1996–1998, 1999–2001, and 2002–2004).

Figure S2. Prevalence ratios of wheezing in children according to maternal type of diabetes versus children of mothers with no diabetes with and without further adjustment for maternal prepregnancy body mass index in the simple bias analysis



We did not have information on prepregnancy BMI in the main registers available and thus were not able to adjust for it in all the models. To further account for confounding by maternal prepregnancy BMI, we performed a simple bias analysis. For this analysis, we used information obtained from a subgroup of the study population, i.e., singletons born from 1996 to 2002 enrolled in the Danish National Birth Cohort, for whom data on maternal self-reported prepregnancy BMI was collected by telephone interview. The following formula was used to calculate the adjusted prevalence ratio:

$$PR_{adj} = PR_{obs} \frac{PR_{CD1}p_{10} + PR_{CD0}p_{00} + (1 - p_{10} - p_{00})}{PR_{CD1}p_{11} + PR_{CD0}p_{01} + (1 - p_{11} - p_{01})}$$

(Source: Lash TL, Fox MP, Fink AK. *Applying Quantitative Bias Analysis to Epidemiologic Data*. New York, USA: Springer; 2009.)

PR_{CD0}—prevalence ratio of wheezing in children of overweight mothers, PR_{CD1}—prevalence ratio of wheezing in children of obese mothers,

p₀₀—Mothers without diabetes who were overweight, p₀₁—Mothers with specific diabetes who were overweight,

p₁₀—Mothers without diabetes who were obese, p₁₁—Mothers with specific diabetes who were obese.

The association (i.e., PR_{CD0}) between overweight (25 ≤ BMI ≤ 29.9 kg/m²) and early-onset transient wheezing was 1.14, early-onset persistent wheezing 1.19, and late-onset wheezing 0.98.

The association (i.e., PR_{CD1}) between obesity (BMI ≥ 30 kg/m²) and early-onset transient wheezing was 1.25, early-onset persistent wheezing 1.24, and late-onset wheezing 1.11.

The prevalence rate of overweight in mothers without diabetes was 19.7% (i.e., P₀₀), pregestational type 1 diabetes 24.6% (i.e., P₀₁ for pregestational type 1 diabetes), pregestational type 2 diabetes 22.3% (i.e., P₀₁ for pregestational type 2 diabetes), and gestational diabetes 29.1% (i.e., P₀₁ for gestational diabetes).

The prevalence rate of obesity in mothers without diabetes was 8.1% (i.e., P₁₀), pregestational type 1 diabetes 21.7% (i.e., P₁₁ for pregestational type 1 diabetes), pregestational type 2 diabetes 35.9% (i.e., P₁₁ for pregestational type 2 diabetes), and gestational diabetes 38.4% (i.e., P₁₁ for gestational diabetes).